Company intelligence / Profile preview
Innoviva, Inc.
Burlingame, California, United Statesinva.com ↗
- Ownership
- Public · INVA
- Development stage
- Commercial
01
Overview
Innoviva is a diversified holding company with a portfolio of royalties from respiratory assets partnered with GSK, as well as commercial products in critical care and infectious diseases through its Innoviva Specialty Therapeutics division. The company has strategically diversified beyond royalty management through key acquisitions, transforming its focus.
- Therapeutic areas
- OtherPulmonologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
34 assets33 more assets in the full pipeline.
03
Partnerships
GlaxoSmithKline (GSK)Armata
04
Financials
- Market cap
- $1.4B
- Total revenue
- $425.1M
- Enterprise value
- $1.1B
Beyond the preview
Go deeper on Innoviva, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innoviva, Inc..